new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Alnylam Pharmaceuticals Inc patents

Recent patent applications related to Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Alnylam Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Alnylam Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alnylam Pharmaceuticals Inc-related inventors




Date Alnylam Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
03/09/17Compositions and methods for inhibiting expression of cd274/pd-l1 gene
02/16/17Methods and compositions for detecting anti-drug antibodies
02/16/17Quantification of transthyretin and its isoforms
02/02/17Rnai agents modified at the 4'-c position
02/02/17Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases
01/05/17Lipid formulated dsrna targeting the pcsk9 gene
12/29/16Oligonucleotide-ligand conjugates and process for their preparation
12/29/16Irna agents with biocleavable tethers
12/08/16Compositions and methods for inhibition of pcsk9 genes
12/08/16Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
12/01/16Nucleic acid chemical modifications
12/01/16Compositions and methods for inhibiting expression of the pcsk9 gene
11/24/16Ketohexokinase (khk) irna compositions and methods of use thereof
11/17/16Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
10/27/16Dual targeting sirna agents
10/13/16Compositions and methods for inhibiting expression of mylip/idol gene
10/13/16Complement component irna compositions and methods of use thereof
09/15/16Compositions and methods for inhibiting expression of a gene from the ebola virus
09/15/16Compositions and methods for inhibiting expression of transthyretin
09/15/16Compositions and methods for inhibiting expression of the lect2 gene
09/15/16Modified irna agents
09/08/16Serpinc1 irna compositions and methods of use thereof
08/25/16Compositions and methods for the manufacture of lipid nanoparticles
08/25/16Serpina1 sirnas: compositions of matter and methods of treatment
08/25/16Complement component c5 irna compositions and methods of use thereof
08/25/16Compositions and methods for inhibiting expression of the alas1 gene
07/21/16Methods and compositions for inhibiting the function of polynucleotide sequences
07/07/16Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
07/07/16Compositions and methods for inhibiting expression of mutant egfr gene
06/30/16Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
06/30/16Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
06/23/16Conserved hbv and hcv sequences useful for gene silencing
06/23/16Compositions and methods for increasing erythropoietin (epo) production
05/26/16Compositions and methods for inhibiting expression of tmprss6 gene
05/26/16Tmprss6 irna compositions and methods of use thereof
05/05/16Dosages and methods for delivering lipid formulated nucleic acid molecules
04/28/16Compositions and methods for inhibiting expression of the alas1 gene
04/21/16Complement component c5 irna compositions and methods of use thereof
04/14/16Monomers and oligonucleotides comprising cycloaddition adduct(s)
04/14/16Compositions and methods for inhibiting expression of the hamp gene
03/31/16Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
03/24/16Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
03/17/16Therapeutic compositions
03/10/16Rnai modulation of scap and therapeutic uses thereof
02/25/16Carbohydrate conjugates as delivery agents for oligonucleotides
01/28/16Compositions and methods for inhibiting expression of gsk-3 genes
01/28/16Compositions and methods for inhibition of expression of protein c (proc) genes
01/21/16Serpinc1 irna compositions and methods of use thereof
01/21/16Pcsk9 irna compositions and methods of use thereof
01/21/16Compositions and methods for inhibiting expression of factor vii gene
01/21/16Compositions and methods for inhibiting expression of eg5 gene
01/14/16Biodegradable lipids for the delivery of active agents
01/07/16Compositions and methods for inhibiting expression of eg5 and vegf genes
12/10/15Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
12/10/15Compositions and methods for inhibiting expression of a target gene
11/26/15Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
11/05/15Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
10/29/15Improved nucleic acid lipid particle formulations
10/01/15Biodegradable lipids for the delivery of active agents
09/03/15Complement component c5 irna compositions and methods of use thereof
08/27/15Compositions and methods for inhibiting expression of a gene from the jc virus
08/27/15Compositions and methods for inhibiting expression of ikk-b gene
08/20/15Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
07/30/15Nucleic acid chemical modifications
07/23/15Di-aliphatic substituted pegylated lipids
Patent Packs
07/23/15Chemical modifications of monomers and oligonucleotides with cycloaddition
07/16/15Carbohydrate conjugated rna agents and process for their preparation
07/16/15Modified rnai agents
07/09/15Ligand-conjugated monomers
06/18/15Stable non-aggregating nucleic acid lipid particle formulations
04/30/15Carbohydrate conjugates as delivery agents for oligonucleotides
04/30/15Carbohydrate conjugates as delivery agents for oligonucleotides
04/23/15Compositions and methods for inhibiting expression of the alas1 gene
04/09/15Gnaq targeted dsrna compositions and methods for inhibiting expression
04/02/15Compositions and methods for inhibiting expression of cd45 gene
04/02/15Methods and compositions for inhibiting the function of polynucleotide sequences
03/19/155' phosphate mimics
03/12/15Irna agents with biocleavable tethers
03/05/15Glycoconjugates of rna interference agents
01/08/15Irna agents targeting vegf
Patent Packs
01/08/15Rnai modulation of rsv and therapeutic uses thereof
01/08/15Methods and compositions for treating insects
01/08/15Carbohydrate conjugates as delivery agents for oligonucleotides
01/01/15Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
11/27/14Serpina1 irna compositions and methods of use thereof
11/20/14Compositions and methods for inhibiting expression of factor vii gene
11/06/14Method for improving the success rate of hematopoietic stem cell transplants
10/23/14Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
09/25/14Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
09/18/14Conserved hbv and hcv sequences useful for gene silencing
09/18/14Assays and methods for determining activity of a therapeutic agent in a subject
09/11/14Compositions and methods for inhibiting expression of xbp-1 gene
08/21/14Serpina1 sirnas: compositions of matter and methods of treatment
08/07/14Method and medicament for inhibiting the expression of a given gene
08/07/14Method and medicament for inhibiting the expression of a given gene
07/24/14Compositions and methods for inhibiting expression of factor v
07/17/14Pegylated lipids and their use for drug delivery
07/10/14Compositions and methods for inhibiting expression of tmprss6 gene
07/10/14Sequence-specific inhibition of small rna function
06/26/14Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
06/26/14Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
06/12/14Sirna silencing of genes expressed in cancer
06/05/14Bioprocessing
06/05/14Method and process for the degradation of cyclic ethers in ethoxylate-containing actives
05/29/14Compositions and methods for inhibiting expression of cd274/pd-l1 gene
05/22/14Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
05/01/14Lipid formulated dsrna targeting the pcsk9 gene
04/17/14Compositions and methods for inhibiting expression of a target gene
04/10/14Compositions and methods for enhancing production of a biological product
02/20/14Method and medicament for inhibiting the expression of a given gene
Social Network Patent Pack
02/20/14Compositions and methods for inhibiting expression of an rna from west nile virus
02/13/14Folate conjugates
02/13/14Rnai modulation of apob and uses thereof
01/23/14Compositions and methods for increasing erythropoietin (epo) production
01/16/14Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
01/02/14Cell-based bioprocessing
12/26/13Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
12/19/13Compositions for nucleic acid delivery
11/28/13Modified irna agents
10/31/13Compositions and methods for inhibition of pcsk9 genes
Patent Packs
10/24/13Sirna therapy for transthyretin (ttr) related ocular amyloidosis
09/19/13Compositions and methods for inhibiting expression of the hamp gene
09/12/13Multifunctional copolymers for nucleic acid delivery
08/15/13Modified irna agents
08/08/13Methods and compositions for delivery of active agents
08/08/132' and 5' modified monomers and oligonucleotides
08/01/13Compositions and methods for modifying the glycosylation pattern of a polypeptide
08/01/13Biodegradable lipids for the delivery of active agents
08/01/13Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
07/18/13Dual targeting sirna agents
07/18/13Ligand-conjugated monomers
07/11/13Carbohydrate conjugates as delivery agents for oligonucleotides
07/11/13Method and medicament for inhibiting the expression of a given gene
06/27/13Cell-based methods and reagents
06/27/13Method and medicament for inhibiting the expression of a given gene
06/27/13Method and medicament for inhibiting the expression of a given gene
06/27/13Gene amplification and transfection methods and reagents related thereto
06/20/13Compositions and methods directed to treating liver fibrosis
06/13/13Nuclease resistant double-stranded ribonucleic acid
06/06/13Therapeutic compositions
05/23/13Methods and compositions for delivery of active agents
05/23/13Oligonucleotides comprising acyclic and abasic nucleosides and analogs
05/16/13Compositions and methods for inhibiting expression of mylip/idol gene
02/28/13Monomers and oligonucleotides comprising cycloaddition adduct(s)
01/17/13Methods and compositions for delivery of nucleic acids
12/13/12Methods and compositions for treating insects
11/22/12Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
11/08/12Compositions and methods for enhancing production of a biological product
10/25/12Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
10/04/12Rnai modulation of apob and uses thereof
Patent Packs
09/27/12Methods for increasing efficacy of lipid formulated sirna
09/27/12Cosmetic skin care methods and compositions
09/27/12Compositions and methods for delivering rnai using apoe
08/30/12Process for triphosphate oligonucleotide synthesis
07/19/12Lipid formulation
06/21/125' phosphate mimics
06/07/12Oligonucleotide end caps
06/07/12Rnai modulation of aha and therapeutic uses thereof
05/31/12Carbohydrate conjugates as delivery agents for oligonucleotides
05/24/12Lipid compositions
05/03/12Synthetic methods and derivatives of triphosphate oligonucleotides
05/03/12Rnai modulation of tgf-beta and therapeutic uses thereof
04/26/12Lipid formulation
04/19/12Novel lipids and compositions for the delivery of therapeutics
03/22/12Nucleic acid chemical modifications
03/08/12Lipids and compositions for the delivery of therapeutics
02/23/12Lipid containing formulations
02/09/12Chemical modifications of monomers and oligonucleotides with cycloaddition
02/09/12Conserved hbv and hcv sequences useful for gene silencing
02/02/12Novel lipids and compositions for the delivery of therapeutics
Social Network Patent Pack
02/02/12Biodegradable lipids for the delivery of active agents
02/02/12Multiple rna polymerase iii promoter expression constructs
12/22/11Novel lipids and compositions for the delivery of therapeutics
10/27/11Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
10/20/11Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
10/20/11Method of treating neurodegenerative disease
10/13/11Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
10/13/11Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/11Compositions and methods for inhibiting expression of an rna from west nile virus
10/06/11Nuclease resistant double-stranded ribonucleic acid
10/06/11Double-stranded rna structures and constructs, and methods for generating and using the same
09/15/11Transfection kinetics and structural promoters
09/15/11Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
09/08/11Phosphorothioate oligonucleotides and non-nucleosidic phosphorothioates as delivery agents for irna agents
08/18/11Compositions and methods for inhibiting expression of a gene from the ebola virus
08/11/11Process for desilylation of oligonucleotides
07/07/11Rna compositions for modulating immune response
06/02/11Non-natural ribonucleotides, and methods of use thereof
05/26/11Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
05/26/11Compositions and methods for inhibiting expression of nav1.8 gene
Social Network Patent Pack
05/19/11Chemically modified oligonucleotides and uses thereof
05/12/11Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
05/12/11Compositions and methods for inhibiting expression of ikk-b gene
04/28/11Rnai agents comprising universal nucleobases
04/28/11Screening selected amino lipid-containing compositions
04/21/11Method of treating neurodegenerative disease
03/24/11Rnai modulation of the rho-a gene and uses thereof
03/10/11Compositions and methods for inhibiting expression of a gene from the ebola virus
02/10/11Rnai inhibition of influenza virus replication
01/06/11Rnai modulation of aha and therapeutic uses thereof
12/23/10Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
10/21/10Targeting opposite strand replication intermediates of single-stranded viruses by rnai
10/21/10Irna agents with biocleavable tethers
09/30/10Dsrna compositions and methods for treating hpv infections
09/23/10Therapeutic compositions
09/02/10Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
08/26/10Rnai modulation of apob and uses thereof
08/12/10Method of treating neurodegenerative disease
08/05/10Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
07/29/10Influenza polynucleotides, expression constructs, compositions, and methods of use
07/08/10Methods and compositions for inhibiting the function of polynucleotide sequences
07/01/10Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
03/25/10Modified irna agents
03/18/10Compositions and methods for inhibiting expression of factor v leiden mutant gene
03/18/10Chemically modified oligonucleotides
02/04/10Methods and compositions for inhibiting the function of polynucleotide sequences
01/21/10Compositions and methods for inhibiting expression of the myc gene
12/24/09Oligonucleotides comprising a non-phosphate backbone linkage
12/17/09Rnai modulation of apob and uses thereof
12/17/09Olignucleotides comprising a ligand tethered to a modified or non-natural nucleobase
Social Network Patent Pack
11/19/09Ligand-conjugated monomers
11/12/09Oligonucleotides comprising a modified or non-natural nucleobase
11/12/09Oligonucleotides comprising a non-phosphate backbone linkage
10/22/09Compositions and methods for inhibiting expression of factor vii gene
10/15/09Compositions and methods for inhibiting expression of nav1.8 gene
10/01/09Targeting lipids
10/01/09Folate conjugates
09/24/09Methods and compositions for prevention or treatment of rsv infection
09/24/09Carbohydrate conjugates as delivery agents for oligonucleotides
09/24/09Rnai modulation of rsv and therapeutic uses thereof
09/17/09Rnai modulation of rsv and therapeutic uses thereof
08/13/09Glycoconjugates of rna interference agents
07/23/09Processes and reagents for sulfurization of oligonucleotides
07/09/09Method of treating neurodegenerative disease
06/25/09Cationic lipids
02/26/09Compositions and methods for inhibiting the expression of anti-apoptopic genes







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alnylam Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alnylam Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';